-
Ifabotuzumab: Exploring the Role of Anti-EphA3 in Cancer Research(Post)
What You Need to Know About IfabotuzumabWhat is Ifabotuzumab?Ifabotuzumab is a monoclonal antibody targeting EphA3, a receptor tyrosine kinase overexpressed in certain cancers. It plays
BDNF in inflammation and neuropathologies(Post)BDNF Overview Brain-derived neurotrophic factor (BDNF) is a central mediator of neuroplasticity, a term used to describe the ability of neurons
HERV-K group of endogenous retroviruses and cancer(Post)In 2006, upon completion of the Human Genome Project, it was discovered that nearly 8% of the human genome is made up of viral DNA. These viral remnants are composed of ancient germl
Astrocyte Markers: A Guide(Post)Explore the world of astrocytes, crucial star-shaped cells in the brain, and understand how specific markers help study their roles in neural health and disorders. Key Takeaways: Ast
Apoptosis Caspase Pathways: A Closer Look at Cellular Suicide(Post)Apoptosis, or programmed cell death, is a fundamental process that plays a critical role in the development and maintenance of healthy tissues. Central to this process are caspases, a family of cy
Labetuzumab: Revolutionizing Cancer Research with Targeted Therapies(Post)Quick Facts About LabetuzumabWhat is Labetuzumab?Labetuzumab is a monoclonal antibody targeting CEACAM5, a protein overexpressed in various cancers, primarily colorectal carcinoma.How do
T-Cell Engagers and Bispecific Antibodies(Page) Trastuzumab: Revolutionizing HER2-Positive Cancer Treatment & Research(Post)Quick Facts About TrastuzumabWhat is Trastuzumab?Trastuzumab is a monoclonal antibody used to treat HER2-positive breast and gastric cancers. It specifically targets the HER2 protein, re
Coeliac Disease Signaling – Review | Assay Genie(Post)By Ciara Coleman PhD General Introduction Coeliac Disease (CD) is defined as a common, chronic inflammatory disease
Tiragolumab: Unlocking New Horizons in Cancer Immunotherapy(Post)Quick Facts About TiragolumabWhat is Tiragolumab?Tiragolumab is an anti-TIGIT monoclonal antibody developed to enhance immune responses against cancer cells. It is currently under invest
VEGF: Inflammation and Tumourigenesis(Post)What is VEGF? Vascular Endothelial Growth Factors (VEGFs) are a group of homodimeric polypeptides, and are master regulators of vascular development, maintenance and a
Deciphering the Intricacies of TGF-Beta Signaling Pathway(Post)Transforming Growth Factor-Beta (TGF-β) signaling pathway plays a pivotal role in orchestrating various cellular processes, ranging from embryonic development to tissue homeostasis and immune resp
Erk Signal Transduction Explained: Step-by-Step Process & Key Concepts(Post)The ERK signal transduction pathway stands as a fundamental mechanism in cellular biology, orchestrating a wide array of physiological processes, including cell division, differentiation, and surv
Anti-PD-L1: Targeting Tumor Evasion with Immune Checkpoint Blockade(Post)IntroductionCancer cells have developed sophisticated mechanisms to evade the immune system, particularly through the inhibition of T-cell responses. One such mechanism involves the progr
CD80: Amplifying Immune Activation Through Co-Stimulatory Pathways(Post)Introduction to CD80 and Its Role in Immune Activation CD80 is a critical immune checkpoint molecule that plays an essential role in T cell activation through co-stimulatory pathways. Exp
Antibody Seroconversion Response in COVID-19(Post)Seroconversion Implications in SARS-CoV-2 Diagnostic Testing Key Points: COVID-19, the pandemic
Pembrolizumab: Unveiling Its Mechanism and Research Applications with Biosimilars(Post)Key Facts: PembrolizumabIs Pembrolizumab Safe?Pembrolizumab is widely recognized as safe for most patients, with side effects ranging from mild to severe. Commonly reported side effects
Avizakimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About AvizakimabWhat is Avizakimab?Avizakimab is a monoclonal antibody designed to target the CD47 protein, a key checkpoint in immune regulation, particularly in cancer ther
Nadecnemab: Advancing Cancer Research Through Anti-CD47 Targeting(Post)Quick Facts About NadecnemabWhat is Nadecnemab?Nadecnemab is an investigational monoclonal antibody that targets CD47, a key immune checkpoint protein involved in cancer evasion.How Does
Cytokine Release Syndrome and the IL-6 Axis(Page)